SARILUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: RESULTS OF A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY

被引：0
|
作者：
Huizinga, T. W. [1 ]
Kivitz, A. J. [2 ]
Rell-Bakalarska, M. [3 ]
Fleischmann, R. M. [4 ]
Jasson, M. [5 ]
Radin, A. R. [6 ]
Genovese, M. C. [7 ]
机构：
[1] Leiden Univ, Med Ctr, Dept Rheumatol, Leiden, Netherlands
[2] Altoona Ctr Clin Res, Dept Rheumatol, Duncansville, PA USA
[3] Rheumatol & Osteoporosis Outpatient Clin, Warsaw, Poland
[4] 1 Metroplex Clin Res Ctr, Dallas, TX USA
[5] Sanofi, Paris, France
[6] Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA
[7] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 71卷
关键词：
D O I：
10.1136/annrheumdis-2012-eular.1706
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：60 / 60
页数：1
相关论文
共 50 条
  • [31] Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study
    Werth, Victoria P.
    Fleischmann, Roy
    Robern, Michael
    Touma, Zahi
    Tiamiyu, Iyabode
    Gurtovaya, Oksana
    Pechonkina, Alena
    Mozaffarian, Afsaneh
    Downie, Bryan
    Matzkies, Franziska
    Wallace, Daniel
    RHEUMATOLOGY, 2022, 61 (06) : 2413 - 2423
  • [32] Phase 2/3 randomized, placebo-controlled, double-blind study of SC golimumab induction in moderate to Severe UC
    Rutgeerts, P.
    Feagan, B.
    Marano, C.
    Strauss, R.
    Johanns, J.
    Zhang, H.
    Guzzo, C.
    Colombel, J. F.
    Reinisch, W.
    Gibson, P. R.
    Collins, J.
    Jarnerot, G.
    Sandborn, W. J.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 591 - 591
  • [33] Efficacy and Safety of Baricitinb in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis
    Torrelo, A.
    Rewerska, B.
    Paller, Amy
    Prakash, A.
    Zhu, D.
    Pontes, M.
    Wu, Wen-Shuo
    Eichenfield, Lawrence F.
    Boecker, Ulrike
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 99 - 99
  • [34] Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
    Papp, K. A.
    Langley, R. G.
    Sigurgeirsson, B.
    Abe, M.
    Baker, D. R.
    Konno, P.
    Haemmerle, S.
    Thurston, H. J.
    Papavassilis, C.
    Richards, H. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2013, 168 (02) : 412 - 421
  • [35] The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study
    Zhao, Y.
    Wu, L.
    Lu, Q.
    Gao, X.
    Zhu, X.
    Yao, X.
    Li, L.
    Li, W.
    Ding, Y.
    Song, Z.
    Liu, L.
    Dang, N.
    Zhang, C.
    Liu, X.
    Gu, J.
    Wang, J.
    Geng, S.
    Liu, Q.
    Guo, Y.
    Dong, L.
    Su, H.
    Bai, L.
    O'Malley, J. T.
    Luo, J.
    Laws, E.
    Mannent, L.
    Ruddy, M.
    Amin, N.
    Bansal, A.
    Ota, T.
    Wang, M.
    Zhang, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : 633 - 641
  • [36] Treatment of moderate-to-severe psoriasis with oral dimethyl fumarate (BG00012): results of a multicentre, randomized, double-blind, placebo-controlled trial
    Mrowietz, U
    Reich, K
    Spellman, MC
    BRITISH JOURNAL OF DERMATOLOGY, 2006, 154 (01)
  • [37] The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study
    Bagel, Jerry
    Duffin, Kristina Callis
    Moore, Angela
    Ferris, Laura K.
    Siu, Kimberly
    Steadman, Jennifer
    Kianifard, Farid
    Nyirady, Judit
    Lebwohl, Mark
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (04) : 667 - 674
  • [38] Alefacept in combination with methotrexate for the treatment of psoriatic arthritis - Results of a randomized, double-blind, placebo-controlled study
    Mease, Philip J.
    Gladman, Dafna D.
    Keystone, Edward C.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (05): : 1638 - 1645
  • [39] Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial
    Yan, Kexiang
    Li, Fuqiu
    Bi, Xiaodong
    Han, Ling
    Zhang, Zhenghua
    Chen, Rixin
    Li, Yuye
    Zhang, Litao
    Wang, Xiaohua
    Li, Linfeng
    Lu, Jianyun
    Xu, Ai'e
    Yang, Sen
    Lu, Yan
    Sun, Jianfang
    Li, Zhiming
    Zhu, Xiaohong
    Jiang, Meiying
    Zhang, Siping
    Wang, Wenqing
    Li, Yanling
    Meng, Zudong
    Li, Hongyi
    Mou, Kuanhou
    Han, Xiuping
    Li, Shanshan
    Chen, Aijun
    Li, Xin
    Liu, Donghua
    Zhang, Chunlei
    Ji, Chao
    Wang, Yu
    Cheng, Hao
    Cui, Xiaojing
    Yao, Xiaoyan
    Bai, Xiaoyan
    Dong, Guangchao
    Xu, Jinhua
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2025, 92 (01) : 92 - 99
  • [40] Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial
    Guttman-Yassky, E.
    Bahadori, L.
    Brooks, L.
    Clark, K. L.
    Grindebacke, H.
    Ho, C. N.
    Katial, R.
    Pham, T. -H.
    Walton, C.
    Datto, C. J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (10) : E1211 - E1214
12345